• PTC inks $200M Agilis takeover to snag late-phase gene therapy fiercebiotech
    July 26, 2018
    PTC Therapeutics is paying $200 million upfront to acquire Agilis Biotherapeutics. The deal gives PTC ownership of a gene therapy treatment for rare neurotransmitter disease AADC deficiency that is set to go before the FDA next year.
PharmaSources Customer Service